Long-term Effects of CPAP on Lipidemia and Hs-CRP Levels in OSA Patients

Not Applicable

Completed

• Conditions: Obstructive Sleep Apnea; Coronary Heart Disease
• Interventions: Device: Continuous Positive Airway Pressure Ventilator

• Registration Number: NCT02127177
• Lead Sponsor: Chinese Pulmonary Vascular Disease Research Group

Brief Summary

The increased risk of atherosclerotic morbidity and mortality in patients with obstructive sleep apnea (OSA) has been linked to hypertension, insulin resistance, dyslipidemia, and systemic inflammation. The relationship regarding obstructive sleep apnea (OSA) and lipidemia and systemic inflammation is far from conclusion for obesity as a strong confounding factor.

Detailed Description

Obstructive sleep apnea (OSA) is a common sleep disorder characterized by recurrent episodes of partial or complete obstruction of the upper airway during sleep, resulting in sleep fragmentation and oxyhemoglobin desaturation. OSA is recognized as an important public health problem in developed country, affecting 9 and 24% of middle-aged females and males, respectively. OSA, however, is not recognized as an abnormality for the majority and doesn't get more attention from most people in China. Increasing evidence now indicates that severe OSA is associated with increased cardiovascular morbidity and mortality, mainly due to acute myocardial infarction and stroke. Atherosclerosis is a key mechanism for these cardiovascular events. Numerous studies have explored the relationship between hypertension and OSA. And these studies confirms that OSA is an important identifiable cause of hypertension and a raised blood pressure has been shown to fall with effective continuous positive airway pressure (CPAP) treatment. Dyslipidemia, an established independent risk factor for coronary heart disease (CHD) and atherosclerosis, is common in patients with OSA. But there are limited interventional data on OSA and lipidemia, showing controversial results. Several studies9,10 have shown a direct relationship between OSA and lipid profiles, independently of obesity, while other studies have demonstrated that obesity, as a confounding factor, contributed to dyslipidemia among OSA patients.11,12 Taken together, adiposity is a strong confounding factor for interpretation of the causal relationship between dyslipidemia and OSA. Few studies have focused on nonobese patients.10,13 There are only a small number of randomized trials that have examined the effect of CPAP on fasting lipid profiles14,15 and none were specifically designed to evaluate the lipid profiles. Furthermore, most studies assessed the impact of CPAP on OSA-related lipids without statin therapy. In this way, it may be useful to avoid the disturb conditions due to statin treatment. But it is impractical to those patients with OSA and CHD. Since statins, in addition to decreasing hyperlipidemia levels, also inhibit inflammatory cytokines and play a critical role of plaque stabilization in CHD patients. Similarly, the condition existed in the examination of high-sensitivity C-reactive protein (hs-CRP) in CHD subjects with OSA. Therefore, the aims of the present study were (1) to establish whether CPAP therapy decreases lipid profiles and hs-CRP levels in nonobese patients with CHD and OSA, (2) to establish whether a relationship exists between the severity of OSA and levels of these circulating markers, and (3) to demonstrate a possible mechanism for the prevention of cardiovascular disease.

Study Timeline

• Study Start: 2010-01
• Primary Completion: 2013-12
• Study Completion: 2013-12
• Status Verified: 2014-04
• Study First Submitted: 2014-04-24
• Study First Submitted QC: 2014-04-28
• Last Update Submitted: 2014-04-28
• Study First Posted: 2014-04-30
• Last Update Posted: 2014-04-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 78

Inclusion Criteria

• Participants diagnosed with a confirmation of CHD and moderate to severe

Exclusion Criteria

• A body mass index (BMI) ≥ 25 kg/m2
• Established hypertension, diabetes mellitus, predominantly central sleep apnea, hypothyroidism
• A history of smoking, chronic obstructive pulmonary disease, atopy, rhinitis, arthritis
• Pharmacological treatment that could affect lipids and hs-CRP levels
• Epworth Sleepiness Scale (ESS) ≥15
• Diagnosed with malignant cancer with a life expectancy of less than 1 years
• Severe psychiatric disease, sustained excessive alcohol use, New York Heart Association Class III-IV degree
• Declined to participate or were unable to give informed consent.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cpap	Continuous Positive Airway Pressure Ventilator	-

Primary Outcome Measures

Name	Time	Method
lipid profiles	baseline, Change from baseline lipids at 6 months，Change from baseline lipids at 12 months	plasma fasting lipid profiles were measured at baseline, 6months，and 12months.

Secondary Outcome Measures

Name	Time	Method
High-sensitivity C-reactive protein	baseline,Change from baseline high-sensitivity C-reactive protein at 6 months,Change from baseline high-sensitivity C-reactive protein at 12 months	Fasting plasma high-sensitivity C-reactive protein was analyzed at baseline,6 months,and 12 months.

Trial Locations

Locations (1)

center of pulmonary vascular disease, Fuwai hospital; 🇨🇳 Beijing, China